Baumkötter, Rieke
Yilmaz, Simge
Zahn, Daniela
Fenzl, Katharina
Prochaska, Jürgen H.
Rossmann, Heidi
Schmidtmann, Irene
Schuster, Alexander K.
Beutel, Manfred E.
Lackner, Karl J.
Münzel, Thomas
Wild, Philipp S.
Funding for this research was provided by:
European Regional Development Fund and the Ministry of Science and Health of the State of Rhineland-Pala (84009735, 84009735, 84009735)
European Regional Development Fund and the Ministry of Science and Health of the State of Rhineland-Palatinate (84007232)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Received: 15 March 2022
Accepted: 26 September 2022
First Online: 31 October 2022
Declarations
:
: The Gutenberg COVID-19 Study was approved by the local ethics committee of the “Landesärztekammer Rheinland-Pfalz” (reference no.: 2018–13720). Participating individuals provided a written informed consent before study enrolment. All study procedures were conducted in accordance with Good Epidemiological Practice and the guidelines of the Declaration of Helsinki.
: Not applicable.
: Outside the submitted work, P.S.W. reports grants from Bayer AG, non-financial grants from Philips Medical Systems, grants and consulting fees from Boehringer Ingelheim, grants and consulting fees from Novartis Pharma, grants and consulting fees from Sanofi-Aventis, grants, consulting and lecturing fees from Bayer Health Care, grants and consulting fees from Daiichi Sankyo Europe, lecturing fees from Pfizer Pharma, lecturing fees from Bristol Myers Squibb, consulting fees from Astra Zeneca, consulting fees and non-financial support from Diasorin and non-financial support from I.E.M. P.S.W is PI of the German Center for Cardiovascular Research (DZHK) and principal investigator of the DIASyM research core (BMBF DIASyM research core (BMBF 161L0217A). J.H.P received funding for lecturing by Bayer AG and Boehringer Ingelheim outside the topic of this work. The remaining authors report no conflict of interest.